New Research Finds Abbott's Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery BlockagesPRNewsWire • 06/26/20
New Late-Breaking Data Highlight Impact of Abbott's Minimally Invasive Structural Heart TherapiesPRNewsWire • 06/25/20
Abbott Laboratories Stock May Be Setting Up For New Run After Hitting All-Time HighInvestors Business Daily • 06/22/20
Is Abbott Stock A Buy As Worries Of A Second Coronavirus Wave Spread?Investors Business Daily • 06/15/20
2 Million Patients And Beyond: Abbott’s FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With DiabetesForbes • 06/15/20
Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance StandardsPRNewsWire • 06/15/20
New Late-Breaking Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1C Levels in People with Type 2 Diabetes Using Insulin or NotPRNewsWire • 06/13/20